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Multi-center screening of the Pathogen Box 
collection for schistosomiasis drug discovery
Martina Maccesi1†, Pedro H. N. Aguiar2†, Valérian Pasche3,4†, Melody Padilla1, Brian M. Suzuki1, 
Sandro Montefusco1,5, Ruben Abagyan1, Jennifer Keiser3,4* , Marina M. Mourão2* and Conor R. Caffrey1*
Abstract 
Background: Over the past five years, as a public service to encourage and accelerate drug discovery for diseases 
of poverty, the Medicines for Malaria Venture (MMV) has released box sets of 400 compounds named the Malaria, 
Pathogen and Stasis Boxes. Here, we screened the Pathogen Box against the post-infective larvae (schistosomula) of 
Schistosoma mansoni using assays particular to the three contributing institutions, namely, the University of Califor-
nia San Diego (UCSD) in the USA, the Swiss Tropical and Public Health Institute (Swiss TPH) in Switzerland, and the 
Fundação Oswaldo Cruz (FIOCRUZ) in Brazil. With the same set of compounds, the goal was to determine the degree 
of inter-assay variability and identify a core set of active compounds common to all three assays. New drugs for schis-
tosomiasis would be welcome given that current treatment and control strategies rely on chemotherapy with just 
one drug, praziquantel.
Methods: Both the UCSD and Swiss TPH assays utilize daily observational scoring methodologies over 72 h, whereas 
the FIOCRUZ assay employs XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium 
hydroxide) at 72 h to measure viability as a function of  NAD+/NADH redox state. Raw and transformed data arising 
from each assay were assembled for comparative analysis.
Results: For the UCSD and Swiss TPH assays, there was strong concordance of at least 87% in identifying active and 
inactive compounds on one or more of the three days. When all three assays were compared at 72 h, concordance 
remained a robust 74%. Further, robust Pearsonʼs correlations (0.48–0.68) were measured between the assays. Of 
those actives at 72 h, the UCSD, Swiss TPH and FIOCRUZ assays identified 86, 103 and 66 compounds, respectively, of 
which 35 were common. Assay idiosyncrasies included the identification of unique compounds, the differential ability 
to identify known antischistosomal compounds and the concept that compounds of interest might include those 
that increase metabolic activity above baseline.
Conclusions: The inter-assay data generated were in good agreement, including with previously reported data. A 
common set of antischistosomal molecules for further exploration has been identified.
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Background
Schistosomiasis is a parasitic disease caused by trema-
todes of the genus Schistosoma. The disease is endemic 
in 78 countries and preventive chemotherapy of at least 
206 million people was necessary in 2016 [1]. Of con-
cern for such a prevalent disease, treatment and control 
relies on mass chemotherapy with just one drug, prazi-
quantel (PZQ) [2, 3]. PZQ is safe, active against all spe-
cies of Schistosoma and is affordable, or distributed free 
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of charge. However, the increasing distribution of what is 
very often a sub-curative drug may encourage the emer-
gence of PZQ-tolerant, or worse, PZQ-resistant parasites 
[3–5], an alarming prospect in the absence of any back-
up drug.
Unlike the case for other global infectious diseases of 
poverty, schistosomiasis has lacked the prioritization 
necessary to establish trans-national, public-private drug 
development programmes that support the synthesis 
of small molecule chemical libraries, high throughput 
screening systems and the discovery expertise to identify 
and advance compounds to the clinic. Allied to this is the 
greater difficulty, logistics and costs needed to maintain 
and handle the schistosome parasite compared to the 
self-replicative single-celled organisms like malaria or the 
kinetoplastid parasites that are relatively easy to culture 
and amenable to automated liquid handling robotics. 
Accordingly, schistosome drug discovery remains frag-
mented across the academic sector with its more limited 
resources.
In the last decade, the realization that the ever-increas-
ing distribution of just one drug to sustain the manage-
ment of schistosomiasis is untenable has motivated the 
development of a number of phenotypic screening para-
digms to identify new small molecules of interest. Many 
of these have coalesced around the application of Schisto-
soma mansoni schistosomula (post-infective larvae) [6–
8]. These can be harvested in their tens of thousands, are 
reasonably amenable to liquid handling and have been 
used as the entry-point to screening and triaging the 
larger ‘industrial-scale’ of small molecule collections for 
subsequent tests against the more limiting adult parasite 
which, although directly responsible for disease morbid-
ity via their eggs, can only be obtained in small numbers 
and from small vertebrate animals. A plethora of schis-
tosomula assays with different read-outs has been devel-
oped [6, 8–11].
Over the same period, the Medicines for Malaria 
Venture (MMV) has made available to the drug dis-
covery community a number of box sets each contain-
ing 400 well-annotated small molecules that have been 
validated in various disease contexts. These include the 
Malaria Box [12], Pathogen Box [13], Stasis Box and, 
most recently, the Pandemic Box. All, bar the last box, 
have been screened against schistosomes in culture/in 
vivo and the data made publicly available [12, 14–16]. 
Because the general interpretability of data arising from 
the phenotypic screening of schistosomula with the vari-
ous MMV-supplied boxes (and other small molecules) 
may have been influenced by the particular assay meth-
odology employed, we took the opportunity to perform 
an inter-institutional phenotypic evaluation of the Patho-
gen Box. The study involved teams from the University 
of California San Diego (UCSD), the Swiss Tropical and 
Public Health Institute (Swiss TPH), and the Fundação 
Oswaldo Cruz (FIOCRUZ). With the same chemical 
matter in hand, the goals were to identify a core set of 
active anti-schistosomal compounds of interest for future 
preclinical pursuit and highlight some distinct features of 
each particular assay.
Methods
Compounds
The Pathogen Box collection contains 400 compounds 
distributed in five 96-well plates and dissolved in 10  μl 
of pure dimethyl sulfoxide (DMSO) at a concentration 
of 10 mM. Plates were shipped on dry ice to each of the 
three institutions by the MMV. Supporting information 
for the compound collection can be found at https ://
www.mmv.org/mmv-open.
Life‑cycle of S. mansoni at UCSD and preparation 
of schistosomula
The NMRI isolate of S. mansoni is maintained by passage 
through Biomphalaria glabrata snails (NMRI line) and 
3–5  week-old, female Golden Syrian hamsters (Envigo, 
Placentia, CA, USA) as intermediate and definite hosts, 
respectively [6, 17]. The acquisition, preparation and in 
vitro maintenance of post-infective larvae (schistoso-
mula) are described as follows. Briefly, infected patent 
snails were induced to shed infective larvae (cercariae) 
under a lamp for up to 2 h. Cercariae were concentrated 
over ice for up to 1 h and then mechanically transformed 
to schistosomula via tail-shearing through a 22 gauge 
micro-emulsifying needle attached to two 10 ml syringes 
(passaged back and forth 12 times) [18]. Schistosomula 
were washed in ice-chilled Basch Medium 169 [19] (con-
taining 100  U/ml penicillin and 100  mg/ml streptomy-
cin). Schistosomula were collected and washed three 
times in the same medium and kept on ice for a maxi-
mum of 1 h before distribution into assay plates contain-
ing compounds.
In vitro phenotypic assay of schistosomula at UCSD
The assay was performed as described [6, 20, 21]. Essen-
tially, stock Pathogen Box compounds were diluted in 
DMSO to a 2 mM concentration and 1 µl manually spot-
ted into transparent, U-bottomed 96-well assay plates 
(Costar 3367). Chilled Basch Medium 169 (100  µl; con-
taining 100 U/ml penicillin, 100 mg/ml streptomycin and 
4% heat-inactivated FBS (Corning Mediatech, New York, 
USA) was then added to mix the compound and this was 
followed by another 100 µl of medium containing 40–50 
schistosomula. The final concentration of compound 
and DMSO was 10  µM and 0.5%, respectively. Each 
compound was tested in duplicate and solvent controls, 
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containing 0.5% DMSO only, were placed in columns 1 
and 12 of each plate. Assay plates were placed into plas-
tic boxes humidified with wet tissue and these were incu-
bated at 37 °C in a 5%  CO2 environment.
Phenotypic changes in the schistosomula were visu-
ally recorded at 24, 48 and 72 h using a Zeiss Axiovert 
A1 inverted microscope (100×) as described [6, 22–24]. 
Briefly, simple descriptors that describe the effects of 
compounds on the parasites (changes in shape, motility 
and density) are employed. To allow for comparisons of 
compound activity, each descriptor is awarded a ‘sever-
ity score’ of 1 and these are added up to a maximum 
score of 4. Evidence of degeneracy or death is awarded 
the maximum score of 4 (raw data shown in Additional 
file  1: Table  S1). Scores were averaged across the dupli-
cate wells.
Life‑cycle of S. mansoni at the Swiss TPH and preparation 
of schistosomula
The procedures to maintain the S. mansoni (Liberian 
strain) life-cycle, harvest cercariae and obtain schisto-
somula for in vitro testing are described elsewhere [8]. 
As detailed previously, the cercariae were mechanically 
transformed into schistosomula using two syringes con-
nected by a Luer-Lok® connector (B. Braun Melsungen 
AG, Melsungen, Germany) [8, 18, 25]. Schistosomula 
were adjusted to a concentration of 50 units/100 µl and 
incubated for at least 12 h at 37 °C in a 5%  CO2 environ-
ment before use [14].
In vitro phenotypic assay of schistosomula at the Swiss TPH
On the day of the first drug assay, the 10 mM stock solu-
tions of the Pathogen Box compounds were diluted (1:10) 
in Medium 199 (Gibco, USA) supplemented with 5% fetal 
calf serum (FCS; Bioconcept AG, Allschwil, Switzerland) 
and an antibiotic cocktail developed previously [26]. The 
drug plates were then stored at − 20 °C upon further use. 
In flat-bottom 96-well plates, each compound was tested 
in duplicate at a concentration of 10 µM. Every test plate 
included two negative controls wells containing 0.1% 
DMSO. Assay plates were incubated at 37 °C in a 5%  CO2 
environment.
Phenotypic changes were visually recorded (10× mag-
nification) at 24, 48 and 72 h using a previously described 
scoring method [8, 27]. Briefly, each well was scored 
using a quarter point descending scale from 3 to 0. The 
maximum score of 3 was assigned to wells containing 
schistosomula with normal movement and for which no 
morphological changes were apparent. A score of 2 was 
assigned when the overall movement in the well was 
reduced (or abnormally increased) and when morpho-
logical changes became apparent, i.e. increase in granu-
larity, swelling, etc. A score of 1 was applied when almost 
no movement and more severe morphological alterations 
were observed. Finally, a score of zero indicated worm 
death (no movement and a complete loss of integrity). 
The antischistosomal effect was expressed as a frac-
tion of the average test scores compared to the average 
score of the negative control wells using Microsoft Excel 
as (1 −  average(test)/average(control)) [8]. For the assay 
to be considered valid, a minimal average score of 2 was 
required in the control wells.
Life‑cycle of S. mansoni at FIOCRUZ and preparation 
of schistosomula
Cercariae of S. mansoni (LE strain) were harvested 
from B. glabrata (Barreiro strain). Schistosomula were 
obtained by mechanical transformation of cercariae 
using a protocol adapted from that previously described 
[19]. Briefly, cercariae were distributed into 50 ml conical 
tubes and allowed to settle on ice for 60 min. Cercariae 
were concentrated by centrifugation at 1000×g for 3 min 
at 4 °C, followed by resuspension in Medium 199 (with-
out phenol red; Cat. # M3769, Sigma-Aldrich, Buchs, 
Switzerland) supplemented with 100 U/ml penicillin and 
100  μg/ml streptomycin (GIBCO, Thermo Fisher Sci-
entific, Waltham, MA, USA). Cercariae were mechani-
cally transformed by passing them four times through a 
22-gauge syringe needle followed by 10 cycles of wash-
ing and sedimentation. Schistosomula were distributed 
in flat-bottom 96-well culture plates at 200 parasites/well 
in a final volume of 195 µl, and incubated at 37 °C and 5% 
 CO2 for 24 h in the same medium supplemented with 2% 
heat-inactivated FBS (GIBCO, Thermo Fisher Scientific).
In vitro phenotypic assay of schistosomula at FIOCRUZ
XTT (sodium-2,3-bis-[2-methoxy-4-nitro-5-
sulfophenyl]-2H–tetrazolium-5-carboxanilide) was 
used as an indicator of schistosomula metabolic activ-
ity by the reduction of the yellow tetrazolium salt XTT 
to an orange formazan product [28, 29]. XTT was dis-
solved in Medium 199 without FBS to prepare a 1 mg/
ml solution and the electron coupling reagent, N-methyl 
dibenzopyrazine methyl sulfate (PMS; Cat. # P9625, 
Sigma-Aldrich) was dissolved at 0.383  mg/ml in PBS. 
Both the XTT and PMS solutions were filtered through 
a 0.2 µm pore size membrane and stored at – 20 °C until 
use. Pathogen Box compounds were diluted to 400  µM 
from a 10 mM stock concentration in Medium 199 (with-
out phenol red) in V-bottom 96-well assay plates. After-
wards, 5 µl of the diluted compounds were added to the 
culture plates that contained 200 parasites/well in 200 µl 
(10  µM final concentration of compound). Incubations 
were maintained for 48 h at 37 °C and 5%  CO2. The XTT 
labeling mixture was prepared by mixing the XTT and 
PMS solutions in a 50:1 ratio and 40  µl of the mixture 
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was added to each well of the assay plate. The incubations 
were continued for a further 24 h at 37  °C and 5%  CO2 
and the absorbance at 450  nm (reference wavelength of 
690 nm) was determined using a SpectraMax M5 micro-
plate reader (Molecular Devices, San Jose, CA, USA). 
Positive and negative controls comprised heat-killed 
parasites and parasites incubated in the presence of 0.1% 
DMSO, respectively. All compounds were tested in dupli-
cate in two independent experiments, totaling four wells 
for each compound. Schistosomula viability was deter-
mined using absorbance values applied to the following 
equation:
where “Sample” is the absorbance measured in each well 
containing parasites tested with compounds, and “Nega-
tive control” and “Positive control” represent the average 
absorbance measured in each of the respective controls.
Data analysis
The phenotypic scores generated by UCSD and Swiss 
TPH, and the percentage viability data generated by 
FIOCRUZ are presented in Additional file  1: Table  S2. 
Active compounds were identified as follows: an UCSD 
assay score of ≥ 2, a Swiss TPH drug effect of ≥ 0.5 and 
a viability of ≤  50% for the FIOCRUZ assay. The data 
from the three assays were also mathematically trans-
formed (below) to obtain activity values within the same 
range and thus facilitate direct comparisons (Additional 
file 1: Table S3). Before running the transformation, the 
raw data were inspected. For some of the compounds 
tested in the Swiss TPH assay, negative viability values 
were obtained when the scores of the test compounds 
surpassed the scores in the control wells. These were 
converted to zero to indicate inactivity. Similarly, in the 
FIOCRUZ assay, compounds inducing an increase over 
the 100% baseline viability of the DMSO controls were 
not included in the data transformation process. How-
ever, some of these compounds that increased activity 
over baseline were also associated with antischistosomal 
activity in at least one of the other two assays and these 
are discussed below. Finally, because the scoring methods 
applied were opposite to one another, i.e. for the UCSD 
and Swiss TPH, the greater the value the more active the 
compound, whereas for FIOCRUZ, the reverse was the 
case, the raw data values were inverted to be consistent 
across all three groups. The data were then transformed 
in a span range from 0 (inactive) to 1 (most active) using 
the following equation:
% Viability =
(Sample− Positive control)
(
Negative control− Positive control
) × 100
Transformed data =
(x−median)
(max(x)−median)
The median was selected as the threshold below 
which all the compounds were considered inactive. We 
employed the median instead of the minimum value of 
each series given that the majority of compounds were 
inactive. Data analysis was performed using Micro-
soft Office Excel and Molsoft ICM software [30]. For 
the transformed data, the Pearsonʼs correlation was 
calculated between pairs of data sets. The value for the 
F-distribution was also calculated to determine whether 
the correlation values occurred by chance or not. A low 
F-distribution value indicates that there is a low probabil-
ity that the correlation between activity data occurred by 
chance. Finally, data for the normalized median activity 
score at 72 h were generated in R (version 3.6.0) using the 
ggplot2 package (version 3.2.0) [31].
Results and discussion
Active and inactive Pathogen Box compounds identified 
among the three institutions
Schistosoma mansoni schistosomula were screened with 
the 400 constituent compounds of the MMV Patho-
gen Box by three institution-specific assays developed 
by UCSD, the Swiss TPH and FIOCRUZ. The data aris-
ing from each assay were then assembled for compara-
tive analysis (Additional file  1). Our study is relevant 
as, to date, a plethora of schistosomula screening assays 
employing different methodologies (e.g. ATP and 
NAD(P) metabolic indicators, DNA intercalation agents 
such as propidium iodide, and visual- or automated 
image-based systems) and readouts (e.g. percentage 
death,  EC50 value or phenotypic score), have been devel-
oped such that the general interpretability of data may be 
constrained by the particular assay employed [9–11, 24, 
28, 32–34].
The main questions to address were the extent to 
which the data generated are assay-specific and which 
compounds can be considered common actives or non-
actives independent of the assay employed. Table  1 
indicates the degree of concordance in the number of 
actives and non-actives identified across the three assays. 
The complete dataset is presented in Additional file  1: 
Table S2.
For the UCSD and Swiss TPH assays, which employ 
visual interpretations of anti-schistosomal activity as a 
function of time, there was strong concordance of 87% 
in identifying compounds as being either active or inac-
tive at 24, 48 and 72  h (Table  1). When comparing the 
UCSD and Swiss TPH assays with the FIOCRUZ meta-
bolic-based XTT assay at the 72 h time point, agreement 
remained high, i.e. 83% and 78% between FIOCRUZ 
and UCSD, and FIOCRUZ and SWISS TPH, respec-
tively. When data of all three groups were compared at 
72 h, the concordance was lower but still a robust 74%. 
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This lower score might be attributable to the assay differ-
ences and parasite strains. In particular, the single metric 
XTT assay used by FIOCRUZ measures the oxidation of 
NAD(P)H as an indicator of viability [29] whereas visual 
interpretations of activity used by UCSD and the Swiss 
TPH are more holistic by identifying changes in features 
such as size, shape, color and motility, relative to DMSO 
controls.
Because both the UCSD and Swiss TPH assays 
employed daily observations at 24, 48 and 72 h, it was 
possible to note some trends for those compounds 
declared as active. The number of unique actives identi-
fied by UCSD decreased over time [44, 31 and 18 com-
pounds at 24, 48 and 72 h (not counting the FIOCRUZ 
component at 72  h), respectively] (Fig  1; Additional 
file  1: Table  S4). This was partly due to transiently 
active compounds, whereby changes noted at 24 h 
were no longer obvious at the later time points. Such 
compounds have been noted before [6, 35] and involve 
relatively mild changes in shape and/or motility, and 
with scores no greater than 2. The second trend was the 
increasing proportion of actives that was shared with 
the Swiss TPH assay as a function of time such that by 
72 h, 68 active compounds were shared. These shared 
actives generally involved more progressive, irrevers-
ible and degenerative phenotypes (Additional file  1: 
Table  S2). Nonetheless, at 72 h, UCSD had 18 active 
compounds (of which 10 registered strong scores ≥ 3), 
that were not identified by the Swiss TPH assay: these 
may be due to differences in the assay design and/or 
interpretation, or the parasite strain (NMRI at UCSD 
and Liberian at the Swiss TPH).
In contrast to the UCSD assay, the number of unique 
Swiss TPH actives increased as a function of time from 
seven at 24 h to 35 at 72 h (not counting the FIOCRUZ 
component at 72  h; Fig.  1; Additional file  1: Table  S4). 
This may be due to differences in the screen assessment 
methods or parasite strains. The scoring system used 
by UCSD is based on a range of phenotypic descriptors 
that encompass shape and color, in addition to motility. 
Although these parameters are taken into account in the 
Swiss TPH scoring scale, the emphasis is on motility. A 
closer examination of the 35 compounds identified as 
active by the Swiss TPH at 72 h indicates that 27 had bor-
derline or modest scores of between 0.5 and 0.65 (Addi-
tional file  1: Table  S4). In contrast, and as noted above, 
those actives that were shared between Swiss TPH and 
UCSD at 72  h and the earlier time points tended to be 
more potent, i.e. scores of ≥ 0.75 for Swiss TPH and ≥ 3 
for UCSD.
At 72 h, the FIOCRUZ assay identified 66 actives, less 
than the 86 and 103 actives captured by the UCSD and 
Swiss TPH assays, respectively (Fig.  1; Additional file  1: 
Table  S2). Of these FIOCRUZ actives, 35 were shared 
with both other assays (termed ‘core actives;’ Additional 
file  1: Table  S5), an additional 12 actives were shared 
with either UCSD (six) or Swiss TPH (six), and 19 were 
unique. Of the 35 core actives, the majority (29) were 
strongly active (≤  30% viability) in the FIOCRUZ assay 
and were also registered as strong actives in the other 
two assays (scores ≥  3 and ≥  0.75 for UCSD and Swiss 
TPH, respectively) at 72 h (Additional file 1: Table S5).
As a single-metric assay using the dye XTT, the 
FIOCRUZ assay is designed to specifically measure meta-
bolic viability via NAD(P)H turnover, whereas the other 
two assays are based on the observational appraisals of 
phenotypic effects. Thus, it is anticipatable that the num-
ber of actives captured overall by the XTT assay would 
be less than the observation-based methods as depicted 
in Fig.  1. Nonetheless, the XTT assay has a robust 74% 
concordance with the other two assays and, in terms of 
automation, scalability and stringency, is particularly 
suitable for high-throughput formats [28]. One possibil-
ity for improving the active capture rate of the XTT assay 
Table 1 Degree of concordance in the number of actives and 
non-actives identified in the Pathogen Box between the UCSD 
(U), Swiss TPH (S) and FIOCRUZ (F) assays
Notes: For the times indicated, the percentage (in bold) and number of 
compounds (in parentheses) that were identified as active or non-active 
between the institutions are indicated. Comparisons between UCSD and the 
Swiss TPH were run on a daily basis, whereas comparisons across all three 
groups were possible at the 72-h time point when the XTT assay (FIOCRUZ) was 
completed and the data analyzed
Abbreviation: na, not applicable
Time (h)/
Comparison
U vs S U vs F S vs F U vs S vs F
24 87 (349) na na na
48 87 (348) na na na
72 87 (347) 83 (331) 78 (312) 74 (295) Fig. 1 Active Pathogen Box compounds identified by the three 
institutions. Venn diagram indicating the number of unique or shared 
actives identified by the three assays. Comparisons across all three 
groups were only possible at the 72-h time point when the XTT 
assay (FIOCRUZ) was completed and the data analyzed. U (blue), S 
(magenta) and F (green) represent UCSD, Swiss TPH and FIOCRUZ, 
respectively
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is to introduce a time component; however, this would 
require more parasites and compound, hence the current 
decision to use a single 72 h time point.
The finding of 19 unique XTT hits is intriguing and, 
apart from the possible influence of strain, the result may 
indicate the assay’s particular ability to identify com-
pounds that decrease the metabolic fitness of the parasite 
yet are beyond visual detection in either of the other two 
assays. Indeed, 12 of the 19 compounds decreased viabil-
ity to less than 25% of the control value (Additional file 1: 
Table S4). Based on a PubChem search, we note that four 
of the 19 XTT-active compounds inhibit Plasmodium 
falciparum l-lactate dehydrogenase, which employs 
NADP(H) to catalyze the interconversion of lactate and 
pyruvate. Interference of this metabolic pathway in the 
schistosome would likely be detected by the XTT assay 
as it could interfere with the parasite’s dehydrogenase 
activity.
Finally, the discussion above related to the XTT assay is 
based on measuring a decrease in metabolic activity from 
the 100% baseline. When including those compounds 
that increase activity above baseline, arbitrarily >  130%, 
an additional 34 compounds are identified, and of these, 
nine compounds are also active in at least one of the 
other assays (Additional file 1: Table S2). The association 
between increased metabolic rate and anti-schistosomal 
activity demonstrated here has not been noted before but 
is worthy of consideration going forward.
To allow for direct comparisons of the data arising 
from the three assays, the raw activity data were trans-
formed and ranked on a scale of 0 to 1 from least to most 
active (Additional file 1: Table S3). The transformed data 
were used to calculate the Pearsonʼs correlation and the 
respective value of the F-distribution at the different time 
points. Robust correlation values of 0.61, 0.63 and 0.68 
were recorded at 24, 48 and 72 h, respectively, between 
the UCSD and Swiss TPH assay data, indicating that 
most of the active compounds demonstrated comparable 
activity. As might be anticipated with the XTT assay, the 
Pearsonʼs correlation values were more moderate when 
compared to either the UCSD or Swiss TPH assays at 
72 h (0.46 and 0.50, respectively).
Activity of reference compounds and consistency 
with previous data
Included in the Pathogen Box are 26 reference com-
pounds, i.e. compounds known to be active against and/
or marketed as drugs for various microbial diseases. As 
shown in Fig.  2 (also Additional file  1: Table  S6), eight 
of the 26 reference compounds were identified as active 
in the UCSD and Swiss TPH assays at the 72-h time 
point. Among these were drugs that had been previously 
Fig. 2 Activity of 26 reference compounds in the Pathogen Box as measured by each assay. Data were transformed on a scale of 0 to 1 to allow for 
direct comparisons of the three datasets at the 72-h time point. Data for UCSD (red circles), Swiss TPH (blue squares) and FIOCRUZ (green triangles) 
are indicated
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identified as antischistosomal, namely clofazimine 
[36], mefloquine [37], auranofin [38, 39] and nitazoxa-
nide [6]. Both groups also had unique actives, namely, 
buparvaquone (UCSD) and nifurtimox (Swiss TPH). In 
the Swiss TPH assay, by contrast, PZQ generated a trans-
formed score of 0.4 (raw score of 0.56), i.e. borderline 
active. The discrepancy in the activity between the two 
assays in detecting PZQ may be due to parasite strain or 
scoring methodology.
The FIOCRUZ assay returned three actives among 
the 26 reference compounds, namely, mefloquine, beda-
quilline and clofazimine: each of these was strongly active 
in the other two assays. PZQ was not active in the XTT 
assay. In this context, it is pertinent to note that a previ-
ously employed CellTiter-Glo assay methodology which 
utilizes ATP as the metabolic readout did not identify PZQ 
or oxamniquine, an older marketed drug for treatment of 
schistosomiasis mansoni, as active against schistosomula 
[32]. This contrasts with the morphological and motility 
derangements induced by PZQ as detected here and previ-
ously [6, 40, 41]. We speculate that metabolic-based assays 
like the XTT assay which are designed to measure viability 
in single cells, are prone to missing important anti-schis-
tosomal chemistries that may not affect cellular vitality/
viability per se, but have mechanisms of action of particu-
lar consequence to complex metazoans, e.g. dysregulation 
of the neuromuscular system.
Interestingly, among the reference compounds that 
were inactive in all three assays was miltefosine, which 
was shown to be active against S. mansoni miracidia and 
cercariae in vitro, as well as against eggs, and adult worms 
in vitro and in vivo [42–44]. The mechanism of action 
of miltefosine may depend on the interplay between 
parasite and host. Thus, El-Faham and colleagues [45] 
demonstrated that treating parasites with miltefosine 
enhances serological recognition of defined adult worm 
surface antigens. The absence of activity here may sug-
gest a stage-specific mode of action, i.e. lacking activity 
against schistosomula.
Finally, of note, is the inter-assay consistency in the 
number of shared actives identified here and previously 
during the assembly of the Pathogen Box in 2015. Specifi-
cally, of 13 compounds declared by the MMV as ‘schisto-
somiasis active’, nine had been identified as active in the 
Swiss TPH assay against schistosomula after 72  h (https 
://www.mmv.org/sites /defau lt/files /uploa ds/docs/mmv_
open/Patho gen_Box_Activ ity_Biolo gical _Data_Smile 
s.xlsx). In the present setting and at the same time point, 
six of those nine actives were confirmed by the Swiss TPH 
assay and corroborated by the UCSD assay, with the latter 
identifying one additional compound (Table 2; Additional 
file 1: Table S7). Lastly, the FIOCRUZ assay identified five 
of the same six active compounds, plus three additional 
actives, one of which was shared with UCSD. Overall, 
therefore, there was solid cross-assay consistency and 
recall in confirming actives among those compounds pre-
viously designated by the MMV as ‘schistosomiasis active’.
Actives identified as a function of disease set
Apart from the strong representation from the MMV 
‘schistosomiasis actives’ among the identified hits (Table 2), 
there were also representations from most of the other 
11 sets designated by the MMV as being active against a 
particular disease (Fig.  3; Additional file  1: Table  S8). As 
Table 2 Actives among the three assays for 13 compounds that had been designated earlier as ‘schistosomiasis active’ by the MMV
a Compounds that the Swiss TPH had previously determined as ‘schistosomiasis active’ vs schistosomula at 72 h during the assembly of the Pathogen Box. Active 
compounds are delineated in bold typeface
UCSD Swiss TPH FIOCRUZ (mean ± SD)
MMV ID/Time point (h) 24 48 72 24 48 72 72
MMV688761 4 4 4 1.00 1.00 1.00a − 8.0 ± 2.5
MMV688763 4 4 4 1.00 1.00 1.00a − 5.8 ± 4.9
MMV688762 4 4 4 1.00 1.00 1.00a − 3.4 ± 3.7
MMV688768 3 4 4 1.00 1.00 1.00a 6.4 ± 3.3
MMV688178 0 0 2 0.60 1.00 1.00a 3.1 ± 8.5
MMV676382 4 4 4 0.45 0.68 0.94a 61.7 ± 11.2
MMV688270 2 4 4 0.05 0.00 0.11a 39.0 ± 24.6
MMV688766 0 0 0 0.15 0.17 0.19 0.1 ± 0.4
MMV688313 0 2 0 0.10 0.17 0.28a 14.7 ± 1.7
MMV688771 1 2 0 0.05 0.10 0.16 62.2 ± 7.1
MMV676536 0 0 0 0.10 0.14 0.11a 75.5 ± 36.1
MMV688552 0 0 0 0.15 0.17 0.31 117.5 ± 14.6
MMV1198433 0 0 0 0.10 0.06 0.00 86.0 ± 19.9
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examples, one of four dengue compounds, MMV688543, 
was active, i.e. normalized median activity ≥  0.5, in both 
the UCSD and Swiss TPH assays. Among the 70 kineto-
plastid compounds, eight (MMV658988, MMV676602, 
MMV688273, MMV688283, MMV688372, MMV689244, 
MMV690027 and MMV690102) were active in at least 
two of the assays. Similar findings were made for 11 of 
the 125 malaria compounds (MMV001059, MMV020391, 
MMV020623, MMV022029, MMV022478, MMV023233, 
MMV023985, MMV024114, MMV024406, MMV663250 
and MMV676881), two of the 11 onchocerciasis com-
pounds (MMV671636 and MMV676063), one of the three 
filariasis compounds (MMV687775) and two of 15 toxo-
plasmosis compounds (MMV688364 and MMV688417). 
Among the 116 tuberculosis compounds, 21 were active in 
two or more assays. Finally, among the 11 cryptosporidi-
osis, one hookworm, and three Wolbachia compound sets, 
actives in two or more assays were not identified (Fig.  3; 
Additional file 1: Table S8).
Conclusions
In this study, the Pathogen Box compound set was phe-
notypically screened with S. mansoni schistosomula 
using assays originating from three different institu-
tions, namely, UCSD, the Swiss TPH and FIOCRUZ. 
The study’s goals were to assess the degree of inter-
assay variability and identify a core set of compounds 
that are active across the three assays performed. 
Among the inherent variables were parasite strain, 
culture medium, whether or not the parasites were 
pre-incubated prior to addition of compounds and the 
detection system employed. In this context, field iso-
lates of S. mansoni with differential susceptibilities 
PZQ are known [46] and the choice of culture medium 
can influence the viability of schistosomula [7, 8, 17]. 
Evaluating the possible influences of these variables on 
the data, however, was not a goal of the current study. 
Our data show that concordance in identifying actives 
and non-actives was greatest between the UCSD and 
the Swiss TPH which employ visual assessments of 
phenotypic changes; however, the single-metric XTT 
assay employed by FIOCRUZ maintained the con-
cordance among all groups at a robust 74%. Each assay 
identified unique actives, including the finding with the 
XTT assay that a chemically-induced increase in base-
line metabolic rate is associated with antischistosomal 
activity. Thus, it could be argued that the best strategy 
to increasing the identification of active compounds is 
to combine an observation-based approach with the 
single-metric XTT assay, assuming that the resources 
necessary are not limiting. Overall, a common core set 
of 35 active compounds was identified which could be 
considered for further investigation. In this context, the 
activity of 24 out of the 35 core actives has already been 
tested against adult S. mansoni [15] with 13 compounds 
being active on both developmental stages (Additional 
file  1: Table  S9). These particular hits provide starting 
points for further optimization.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1307 1-019-3747-6.
Fig. 3 Antischistosomal activity as a function of disease set in the Pathogen Box. The Pathogen Box contains compounds for which activity against 
various micro-organisms had been previously determined during the assembly of the collection (disease sets). For each compound (represented 
as a circle), the normalized median activity score at 72 h was calculated and plotted as a function of disease. A grey circle indicates that a median 
activity score of < 0.5 was attributed by all of the screening centers, whereas green, blue and red circles indicate that a score ≥ 0.5 was attributed by 
one, two or all three centers, respectively
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Additional file 1: Table S1. Descriptors and associated severity scores 
applied by UCSD. Table S2. Concordance between the 3 groups for 
active and inactive compounds. Table S3. Data transformation. Table S4. 
Unique hits per group. Table S5. Active compounds shared by all three 
groups (‘core actives’). Table S6. Transformed activity of the reference 
compounds. Table S7. Comparisons with data previously generated for 
the same compounds. Table S8. Transformed activity by disease set. 
Table S9. Core active compounds compared to activity measured previ-
ously by the Swiss TPH against adult S. mansoni.
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